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This policy brief summarizes the evidence and recommendations in the Policy guidelines for collaborative TB and HIV services for injecting and other drug users, which were developed by WHO in collaboration with UNODC and UNAIDS and in consultation with a group of 
technical experts. 
The Policy guidelines outline the detailed evidence and explanation of the recommendations and 
describe the methods, the people involved and the summary of conflicts of interest.
This is part of the Evidence for Action Series jointly produced by WHO, UNAIDS and UNODC (1). 
Others in the series include Effectiveness of interventions to address HIV in prisons, Effectiveness 
of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users and 
Effectiveness of drug dependence treatment in preventing HIV among HIV injecting drug users.
PUrPOSE
The aim of this guidance is to provide a strategic 
approach to reducing TB- and HIV-related morbidity 
and mortality among drug users and their communi-
ties in a way that promotes holistic and person-centred 
services.
Target population
These guidelines are intended for people who are deal-
ing with the population of drug users who have the 
most problematic patterns of use and the greatest risk 
of HIV and TB, especially those who inject drugs.
These guidelines focus particularly on people who are:
◗ using opioid or stimulant drugs, such as 
cocaine or amphetamines, which are illegal to 
buy or supply (unless prescribed) in almost all 
countries;
◗ using them in a way that is harmful to their 
physical or mental health; and
◗ using them in a dependent way, including a 
strong desire to take the drug, difficulty in con-
trolling its use, persisting in using it despite 
harmful effects, giving a higher priority to drug 
use than to other activities and obligations, 
increased tolerance and sometimes a physical 
withdrawal state.
The term “drug user” includes injecting and non-inject-
ing users, unless specified.
◗ Use of alcohol, cannabinoids and tobacco is 
excluded to enable a focus on the most vulner-
able populations.
BACkgrOUND
Injecting behaviour
The main focus is on injecting drug users who are the 
population group with the highest incidence of HIV 
(2). The risk is not linked to any particular drug but 
with unsafe practices using shared injecting equipment.
HIV epidemic in drug users
Injecting drug use is a major mode of HIV transmis-
sion in several regions and is emerging as a concern in 
Africa. It is estimated that maybe as much as 10% of all 
new HIV infections are attributable to injecting drug 
use, and about 2.5 million past and current injecting 
drug users are living with HIV (3).
Among all the estimated 33.2 million [30.6 million – 
36.1 million] (2) people living with HIV, TB is one of 
the commonest AIDS-defining conditions and the lead-
ing cause of death. Both all-cause and TB-associated 
mortality rates are several-fold higher among drug users 
living with HIV than among other people living with 
HIV (4,5).
TB among drug users
Drug use is associated with increased rates of TB dis-
ease and TB infection. People who have TB infection 
without HIV coinfection have a 5–10% lifetime risk 
of developing TB disease, whereas people living with 
HIV have a 5–10% annual risk of developing TB dis-
ease (6).
TB disease rates among drug users in New York City in 
the early 1970s were more than 10 times higher than 
those in the general population (7). Injecting drug users 
have higher TB infection rates than the general popula-
tion (8).
Multidrug-resistant TB poses a threat to TB control, 
with evidence of increases in some countries. Some 
emerging signs indicate that people living with HIV 
may have a higher risk of multidrug-resistant TB. For 
instance, data available from Donetsk Oblast, Ukraine 
and from Latvia indicate that HIV and multidrug-
resistant TB are significantly associated (9). There may 
also be a link with prison settings, where multidrug-
resistant TB rates are often higher (9).
Gender and drug use
Although women comprise a minority of drug users, 
they tend to experience greater negative health and 
social effects than men who use drugs. The links with 
sex work can place women at greater risk of HIV infec-
tion and hence HIV-related TB. They are at great risk 
of marginalization and violence. Women also have 
specific needs related to pregnancy and child-rearing, 
whether for contraception or maternal and child health 
care. The risk of mother-to-child transmission of HIV 
can be reduced by early diagnosis and providing antiret-
roviral therapy (10).
rECOmmENDATIONS
Joint planning
Service delivery is likely to be successful where people 
can access the right intervention at the right time from 
the right service. Services therefore need to be planned 
to meet complex needs, including by actively reaching 
out to drug users and designing services that will reduce 
stigma and encourage take-up.
Recommendation 1
There should be multisectoral coordination at 
the local and national levels to plan, implement 
and monitor TB/HIV activities for drug users. 
This should be done through existing mecha-
nisms if possible.
Recommendation 2
The national strategic plans for TB, HIV and 
substance misuse should clearly define the roles 
and responsibilities of all service providers deliv-
ering services for drug users and should ensure 
the monitoring and evaluation of TB and HIV 
activities for drug users, including treatment out-
comes.
Recommendation 3
Human resource planning should ensure that 
there are adequate numbers of personnel and 
that education and training programmes aim to 
build sustainable effective teams so that all per-
sonnel who have contact with drug users have 
the appropriate level of skill in dealing with TB 
and HIV and drug users.
Recommendation 4
All stakeholders for collaborative TB/HIV serv-
ices for drug users should support and encourage 
TB/HIV operational research to develop the evi-
dence base for efficient and effective implemen-
tation of collaborative TB/HIV activities.
Key interventions
 Preventing TB transmission by 
controlling infection
TB is a contagious disease that is transmitted through 
airborne infectious particles transferred from person to 
person through coughing, sneezing, talking or singing.
Recommendation 5
All congregate settings in the health, drug serv-
ice and criminal justice sectors should have a TB 
infection control plan supported by all stakehold-
ers that includes administrative, environmental 
and personal protection measures to reduce the 
transmission of TB.
Intensified case-finding for TB
The most important symptoms raising suspicion of 
pulmonary TB are a cough for more than two or three 
weeks, sputum production and loss of weight. Greater 
weight loss, diarrhoea and skin disease are more com-
mon among people living with HIV than among peo-
ple who are HIV-negative (11).
Intensified case-finding and treatment of TB among 
people living with HIV reduces mortality and inter-
rupts disease transmission by infectious cases (in the 
household and hospital or clinic settings). At a mini-
mum, trained counsellors or other lay health workers 
can administer a brief questionnaire on TB symptoms 
to screen for active TB.
HIV testing and counselling
The right to know one’s status is fundamental to access-
ing life-saving prevention, treatment and care services.
Recommendation 6
All services dealing with drug users should have 
a case-finding protocol for TB and HIV so that 
staff are aware of the symptoms of TB and HIV 
and can ensure that drug users have access to 
appropriate TB and HIV testing and counsel-
ling, preferably at the service where they initially 
present.
Treatment
Treatment for TB
TB is a curable disease when appropriate antimicrobial 
drugs are available and properly administered. Standard 
TB therapy consists of an initial phase of two months 
of treatment with four different antimicrobial drugs 
given daily under observation and a continuation phase 
of four to six months of at least two antimicrobial drugs 
under as close supervision as possible (DOTS) (11).
Treatment for HIV
With the introduction of antiretroviral therapy, HIV 
infection is in the process of transforming from a pro-
gressive and usually fatal disease to a chronic manage-
able infection.
WHO recommends a standardized public health 
approach to antiretroviral therapy regimens for HIV 
infection (12,13). HIV services should select a single 
first-line regimen and a limited number of second-line 
regimens.
Multiple treatment regimes
In some cases simultaneous medication may be needed 
for multiple conditions including TB, HIV, hepati-
tis B virus and hepatitis C virus, other infections and 
conditions related to drug dependence as well as drug 
dependence itself (14). Despite these challenges, none 
of these are absolute contraindications to standard TB/
HIV treatment regimens and treatment for associated 
illness in drug users.
Recommendation 7
TB and HIV services and services for drug users 
should ensure access to appropriate treatment for 
drug users by using global, regional and national 
clinical guidelines and should work in collabora-
tion to ensure treatment supervision and to sim-
plify the delivery of treatment.
 Preventing TB using isoniazid 
preventive therapy
Isoniazid preventive therapy means that people who 
have been infected with TB, especially people living 
with HIV, use this single anti-TB drug for six to nine 
months to prevent TB infection from progressing to 
TB disease.
Isoniazid preventive therapy is effective for preventing 
active TB disease in TB-infected individuals who are 
also living with HIV. Antiretroviral therapy reduces the 
incidence of TB by as much as 80%, so that provid-
ing antiretroviral therapy to drug users with HIV is also 
effective for preventing active TB, and this effect is also 
additive when used with isoniazid (15).
Recommendation 8
All health services should ensure access to isoni-
azid preventive therapy to drug users living with 
HIV once active TB is reasonably excluded.
 Preventing HIV transmission
Sharing injecting equipment in an unsafe way is 
the greatest risk factor for HIV transmission. Sex 
is also a route of transmission for HIV, such as 
for drug users who may exchange sex for drugs 
or money (16,17).
Recommendation 9
All personnel working with TB suspects and 
patients, people living with HIV and drug users 
should be able to assess risk factors for HIV infec-
tion and transmission and should provide compre-
hensive HIV prevention information and services 
to their clients to minimize these risks. Personnel 
should also be aware of how to protect themselves 
from occupational exposure to HIV and TB.
Overcoming barriers
Models of service delivery
Health outcomes for drug users can be much worse than 
those among the general population. Stigma against drug 
users among health workers, law enforcement person-
nel and social service workers contributes to poor out-
comes (18) as does the need to attend multiple services. 
Women who inject drugs are more likely than men to 
delay approaching health facilities (19). TB and HIV 
services and services for drug users are organized very 
separately in many countries and are not as integrated as 
they could be. Both better case detection and adherence 
in drug users are feasible and imperative for TB and HIV 
programmes. Treatment programmes can help address 
the gap in health outcomes when organized properly.
Recommendation 10
All services dealing with drug users should col-
laborate locally with key partners to ensure uni-
versal access to comprehensive TB and HIV pre-
vention, treatment and care as well as drug treat-
ment services for drug users in a holistic person-
centred way that maximizes access and adher-
ence: in one setting, if possible.
Prisons and other places of detention
Prisoners are often housed in overcrowded facilities 
with inadequate ventilation, hygiene and health care 
services. In many countries drug users are at high risk 
of being imprisoned. Prisoners have a high risk of trans-
mitting TB and HIV infection and a significant prob-
ability of dual TB/HIV infection (20–22). Treatment 
risks being discontinued on transfer in and out of and 
between places of detention.
Recommendation 11
Medical examination upon entry and any 
time thereafter, conforming to internationally 
accepted standards of medical confidentiality 
and care, should be available for all prisoners. 
Prisoners should obtain care equivalent to that 
provided for the civilian population, and care 
should be continuous on transfer in and out of 
places of detention.
Adherence
Adherence interventions among drug users can result in 
treatment completion rates as high as those for other 
people. Poor adherence leads to the development of 
drug resistance, and this may soon be seen as a failure 
not primarily of the drug user but of the health system 
to provide appropriate adherence interventions.
Barriers to adherence vary between settings, so services 
should consult with users and their representatives first 
to find the most effective ways to overcome them and 
the best local solutions. Evidence indicates effectiveness 
for adherence reminders, adherence counselling, con-
tingency management, supervised therapy, opioid sub-
stitution therapy and ancillary services.
Recommendation 12
There should be specific adherence support 
measures for drug users to ensure the best pos-
sible treatment outcomes for TB and HIV infec-
tion and to reduce the risk of development of 
drug resistance and the risk of transmission to 
other people.
Common types of comorbidity
Neither medication for TB nor antiretroviral therapy 
are contraindicated in drug users with hepatitis B or C 
(11,23–25). Many types of comorbidity such as mental 
health problems, hepatitis and ongoing illicit drug use 
may require increased health care supervision, and glo-
bal, regional or national clinical guidelines should be 
followed in managing them.
Recommendation 13
Comorbidity, including viral hepatitis infection 
(such as hepatitis B and C), should not con-
traindicate HIV or TB treatment for drug users. 
Alcohol dependence, active drug use and mental 
health problems should not be used as reasons to 
withhold treatment.
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